68Ga-FAPI在乳腺癌诊断中的研究进展

Research Progress of 68Ga-FAPI in the Diagnosis of Breast Cancer

乳腺癌(Breast cancer, BC)是女性最常见的恶性肿瘤,又称为“粉红杀手”,在癌症相关妇女死亡原因中排第二。成纤维细胞活化蛋白(fibroblast activation protein, FAP),高度表达于肿瘤相关成纤维细胞中,近年来,基于喹啉设计的小分子FAP抑制剂(FAP inhibitor, FAPI)显示出优秀的FAP亲和力,在乳腺癌中摄取量较高。随着技术的发展,68Ga标记的FAPI在乳腺癌的诊断中得到了进一步的发展。本文就近年来68Ga-FAPI在乳腺癌中的临床研究和应用进展做简要综述,以提高其临床应用效益。

Breast cancer (BC) is the most common malignancy in women, also known as the “Pink Killer”. BC is the second leading cause of cancer-related death in women. Fibroblast activation protein (FAP) is highly expressed in tumor-associated fibroblasts. Recently, small molecule FAP inhibitor (FAPI) based on quinoline design has shown an excellent affinity for FAP, high intake in breast cancer. With the development of technology, 68Ga-labeled FAPI (68Ga-FAPI) has been further developed in the diagnosis of breast cancer. In this review, the clinical research and application of 68Ga-FAPI in breast cancer were reviewed to improve the clinical benefit.